Moreover, DAMPs produced during paclitaxel treatment can activate the NOD2 signaling and worsen the tumor microenvironment, resisting the therapeutic effect of paclitaxel, but NOD2 antagonist enables the sensitization of chemotherapeutic response (Dong et al., 2017). This evidence concerns the gene NOD2 and neoplasm.